Multifocal motor neuropathy  improved by IVIg

Federico, Piera; Zochodne, Douglas W.; Hahn, Angelika F.; Brown, William F.; Feasby, Tom

doi:10.1212/wnl.55.9.1256

Cited by 262 publications

(162 citation statements)

References 28 publications

Supporting

Mentioning

143

Contrasting

Unclassified

Order By: Relevance

“…IVIG remains the treatment of choice for patients with MMN [5,[71][72][73][74][75][76]. IVIG is recommended as a first-line therapy, based on a meta-analysis of 4 randomized, double-blind, placebocontrolled, trials [73][74][75][76], involving a total of 34 patients: 78 % of study participants had a significant short-term improvement in strength, selected as primary outcome measure, following IVIG treatment compared with 4 % following placebo [77].…”

Section: Ivigmentioning

confidence: 99%

“…IVIG is recommended as a first-line therapy, based on a meta-analysis of 4 randomized, double-blind, placebocontrolled, trials [73][74][75][76], involving a total of 34 patients: 78 % of study participants had a significant short-term improvement in strength, selected as primary outcome measure, following IVIG treatment compared with 4 % following placebo [77]. Another RCT was conducted in the USA and Canada to assess the efficacy, safety, and tolerability of 10 % liquid IVIG in 44 patients with MMN [78].…”

Section: Ivigmentioning

confidence: 99%

See 1 more Smart Citation

Immunotherapy in Peripheral Neuropathies

Léger¹,

Guimarães‐Costa²,

Muntean³

2016

Neurotherapeutics

View full text Add to dashboard Cite

Immunotherapy has been investigated in a small subset of peripheral neuropathies, including an acute one, Guillain-Barré syndrome, and 3 chronic forms: chronic inflammatory demyelinating polyradiculoneuropathy, multifocal motor neuropathy, and neuropathy associated with IgM anti-myelin-associated glycoprotein. Several experimental studies and clinical data are strongly suggestive of an immune-mediated pathogenesis. Either cell-mediated mechanisms or antibody responses to Schwann cell, compact myelin, or nodal antigens are considered to act together in an aberrant immune response to cause damage to peripheral nerves. Immunomodulatory treatments used in these neuropathies aim to act at various steps of this pathogenic process. However, there are many phenotypic variants and, consequently, there is a significant difference in the response to immunotherapy between these neuropathies, as well as a need to improve our knowledge and long-term management of chronic forms.

show abstract

Section: Ivigmentioning

confidence: 99%

Section: Ivigmentioning

confidence: 99%

Immunotherapy in Peripheral Neuropathies

Léger¹,

Guimarães‐Costa²,

Muntean³

2016

Neurotherapeutics

View full text Add to dashboard Cite

show abstract

“…Yet, this is clearly different in MMN, where PE and even more GS might worsen the course of the disease. [56][57][58][59] Paraproteinemic neuropathy is another rare subtype of inflammatory neuropathy. Here, demyelination is often associated with the presence of clonally restricted IgM antibodies directed against myelin.…”

Section: Plasma Exchange In Multiple Sclerosis Relapsesmentioning

confidence: 99%

Plasmapheresis for neuroinflammatory disorders

Schröder

Linker

Gold

2010

Clinical & Exp Neuroim

View full text Add to dashboard Cite

Nowadays, therapeutic plasma exchange (PE) is the most common apheresis procedure. Plasma is separated from corpuscular blood constitutents and replaced with a substitution fluid. Thus, PE is a non‐specific treatment modality. Its therapeutic effect is based on the removal of circulating, pathogenic immune factors, including autoantibodies. To date, PE is well established for several immune mediated neurological disorders. Whilst the first experience was acquired in acute life‐threatening conditions, such as the treatment of Guillain–Barré syndrome or myasthenic crisis, therapeutic success was later achieved in other chronic autoimmune diseases; PE was applied successfully in chronic inflammatory demyelinating polyneuropathy, paraproteinaemic polyneuropathy, stiff‐person syndrome and might also be tried in autoimmune diseases of paraneoplastic origin. From a novel aspect, PE was also established as an escalation therapy for steroid unresponsive relapses of multiple sclerosis, and thus has gained even more widespread attention. Humoral disease mechanisms dominate even more in neuromyelitis optica, as a subtype of MS, and usually respond to PE. Adding to its increasing application in clinical practice, the procedure is usually well tolerated. Possible adverse reactions of PE arise from the large‐size vascular access site, the use of replacement fluids and the need for anticoagulation. (Clin. Exp. Neuroimmunol. doi: 10.1111/j.1759‐1961.2010.0010.x, 2010)

show abstract

“…Several studies have demonstrated the efficacy of IVIg in MMN, including a few placebocontrolled, double-blind trials. 36,37 Lack of improvement after one, or at most two treatments should be considered as a treatment failure. However, even with intensive IVIg therapy some patients had progression of neurologic deficits.…”

Section: Multifocal Motor Neuropathymentioning

confidence: 99%

Inflammatory Demyelinating Neuropathies and Neuropathies Associated with Monoclonal Gammopathies: Treatment Update

2008

View full text Add to dashboard Cite

Summary:This review focuses on recent data regarding inflammatory demyelinating neuropathies and neuropathies associated with monoclonal gammopathies. We describe both acute and chronic inflammatory neuropathies, and we discuss conditions ranging from mostly cell-mediated to antibody-mediated disorders. These diseases are characterized by proximal and distal sensory motor involvement. Treatments are based on immune-modulation and/or immune-suppression. Work-up sequence and therapeutical modes are discussed in the light of recently published data, with a special interest on new treatment modalities.

show abstract

Multifocal motor neuropathy improved by IVIg

Abstract: IVIg improved conduction block as well as subjective and objective clinical measures of function in patients with MMN.

Cited by 262 publications

References 28 publications

Immunotherapy in Peripheral Neuropathies

Immunotherapy in Peripheral Neuropathies

Plasmapheresis for neuroinflammatory disorders

Inflammatory Demyelinating Neuropathies and Neuropathies Associated with Monoclonal Gammopathies: Treatment Update

Contact Info

Product

Resources

About